advanced search

EXPERT VIEW

CONNECTED DRUG DELIVERY SECTOR OVERVIEW
EXPERT VIEW
Tom Oakley
CONNECTED DRUG DELIVERY SECTOR OVERVIEW
Tom Oakley gives an overview of the state of connected devices in the drug delivery world, touching on various approaches, benefits and challenges in the sector today.
THINK BEYOND THE DEVICE: THE MANY SIDES TO CONNECTIVITY
EXPERT VIEW
Alexander Dahmani
THINK BEYOND THE DEVICE: THE MANY SIDES TO CONNECTIVITY
Alexander Dahmani sheds light on some of the factors, beyond technical design and capabilities, involved in bringing a connected device to market.
THE SMART APPROACH TO HARNESSING DATA
EXPERT VIEW
Tom Lawrie-Fussey
THE SMART APPROACH TO HARNESSING DATA
As the drug delivery world moves to embrace big data, it is important to remember that unseen risks await the unwary. Tom Lawrie-Fussey explains further.
EXTRACTABLES AND LEACHABLES FOR INJECTION DEVICES
EXPERT VIEW
Mark Turner
EXTRACTABLES AND LEACHABLES FOR INJECTION DEVICES
Mark Turner explains the process involved in ensuring that pharmaceutical containers do not inadvertently transmit toxic substances, while maintaining the effectiveness of the active pharmaceutical ingredients (APIs).
THE FUTURE OF DRUG DELIVERY
EXPERT VIEW
Uri Baruch
THE FUTURE OF DRUG DELIVERY
Uri Baruch looks back on how far injectable drug delivery has come in the past thirty years and, with an eye on current trends and the range of innovations in the sector, particularly data and connectivity technology, looks forward to what the future may hold.
PHARMA PARTNERING CONSIDERATIONS FOR INJECTION DEVICE COMPONENTS
EXPERT VIEW
Adam Shain
PHARMA PARTNERING CONSIDERATIONS FOR INJECTION DEVICE COMPONENTS
In the modern world of injectable drugs, one of the major considerations for pharma is choosing partner companies for the development and manufacture of the injection device components. Adam Shain, discusses several of the considerations that go into ensuring that the best possible partner is selected.
A POSITIVE SPIN ON DPI FORMULATION
EXPERT VIEW
Bert Dekens
A POSITIVE SPIN ON DPI FORMULATION
Bert Dekens outlines some of the considerations that go into developing and processing dry powder inhaler formulations, and discusses the merits of conical high-shear mixers.
POWDER MICRODOSING WITH 100% IN-LINE FILL WEIGHT CONTROL BY X-RAY
EXPERT VIEW
Dr Karlheinz Seyfang
POWDER MICRODOSING WITH 100% IN-LINE FILL WEIGHT CONTROL BY X-RAY
Karlheinz Seyfang discusses the need for filling verification in pre-metered DPI blister filling lines, going on to detail the role X-ray analysis could play in an automated verification process.
THE NEW EU MEDICAL DEVICE REGULATIONS – IMPLICATIONS FOR INHALATION DEVICES
EXPERT VIEW
Mary Hutchens
THE NEW EU MEDICAL DEVICE REGULATIONS – IMPLICATIONS FOR INHALATION DEVICES
Mary Hutchens gives an overview of some of the changes wrought by last year’s introduction of the new EU Medical Device Regulation, with a specific view to its effect on inhalation devices and inhaled medical products.
CHOOSING THE RIGHT DOSATOR FOR DPI DOSING
EXPERT VIEW
Jamie Clayton
CHOOSING THE RIGHT DOSATOR FOR DPI DOSING
Jamie Clayton, Rajeev Dattani and Dave Seaward discuss the operation of dosators for reliable and accurate filling of DPI capsules and blisters.
MEETING FUTURE NEEDS FOR RESPIRATORY DRUG DELIVERY DEVELOPMENT
EXPERT VIEW
Mark Knowles
MEETING FUTURE NEEDS FOR RESPIRATORY DRUG DELIVERY DEVELOPMENT
Mark Knowles and Collette Johnson explore the different elements that need to be considered when developing a smart inhalation drug delivery device to ensure that maximum benefit is obtained.
QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?
EXPERT VIEW
Petra Botzem
QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?
Petra Botzem and Thomas Hille discuss the Quality-by-Design approach to the development of transdermal drug delivery systems as laid out in ICH guideline Q8.
FROM PREFILLED SYRINGES TO COMBI-FILLING
EXPERT VIEW
Klaus Ullher
FROM PREFILLED SYRINGES TO COMBI-FILLING
Klaus Ullherr summarises the state of modern packaging technology in the pharmaceutical industry in the light of the biotech boom, ready-to-fill and pre-sterilised containers and the trend towards individualised healthcare.
RECONSTITUTION DEVICES: MIXING, POWER, PACKAGING & REGULATION
EXPERT VIEW
Charlotte Harvey
RECONSTITUTION DEVICES: MIXING, POWER, PACKAGING & REGULATION
Charlotte Harvey discusses the challenge of reconstituting lyophilised drugs, both from the perspective of the drug itself and the delivery device associated with it.
A PATIENT-CENTRIC APPROACH TO THERAPY MANAGEMENT
EXPERT VIEW
Karl Hewson
A PATIENT-CENTRIC APPROACH TO THERAPY MANAGEMENT
Karl Hewson and Uri Baruch discuss the challenges presented by chronic illness, and look ahead to a better future of patient-centric treatment, personalised to each individual’s needs.
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
EXPERT VIEW
Dr Paul Kippax
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
EXPERT VIEW
Di Huang
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.
SUSTAINED RELEASE OCULAR THERAPEUTICS
EXPERT VIEW
Michael O'Rourke
SUSTAINED RELEASE OCULAR THERAPEUTICS
Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.
HOW CONNECTIVITY WILL REMODEL HEALTHCARE
EXPERT VIEW
Dr Marjorie Villien
HOW CONNECTIVITY WILL REMODEL HEALTHCARE
Marjorie Villien and Jerôme Mouly provide a forecast of the place of connectivity in the healthcare market and the significant changes it is likely to bring to both devices and the market itself.
THE PROMISE OF VOICE: CONNECTING DRUG DELIVERY THROUGH VOICE-ACTIVATED TECHNOLOGY
EXPERT VIEW
Chris Franzese
THE PROMISE OF VOICE: CONNECTING DRUG DELIVERY THROUGH VOICE-ACTIVATED TECHNOLOGY
Chris Franzese and Marty Coyne discuss the vast potential that voice-activated technologies, such as Amazon’s Alexa, have in the healthcare market. Running through the challenges posed by data security and human factors, they go on to explain how the rewards voice-activation offers are well worth the effort, spanning the drug delivery experience.
ENERGY HARVESTING: POWERING CONNECTED DRUG DELIVERY DEVICES
EXPERT VIEW
Charlotte Harvey
ENERGY HARVESTING: POWERING CONNECTED DRUG DELIVERY DEVICES
Charlotte Harvey examines the opportunities and practicalities of using energy harvesting technologies in drug delivery devices. With a specific focus on enabling connectivity functionality, Ms Harvey runs through the various aspects of energy harvesting and offers insight on whether it is the right choice for a new device development.
THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR
EXPERT VIEW
Ryan Noble
THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR
Ryan Noble and Tom Lawrie-Fussey discuss the potential of digital innovations to improve understanding of real patient behaviour and consequently increase adherence.
KEY CONSIDERATIONS FOR NON-CLINICAL SAFETY ASSESSMENT OF INHALED BIOPHARMACEUTICALS
EXPERT VIEW
Dr Simon Moore
KEY CONSIDERATIONS FOR NON-CLINICAL SAFETY ASSESSMENT OF INHALED BIOPHARMACEUTICALS
Simon Moore, Kirsty Haprer and Sylwia Marshall highlight some of the key considerations for the development of inhaled biopharmaceuticals, including non-clinical safety assessment.
DOES THE NEW EU MDR SPELL THE END OF GRANDFATHERING?
EXPERT VIEW
Helen Simmons
DOES THE NEW EU MDR SPELL THE END OF GRANDFATHERING?
Helen Simons and Stephanie Ward describe how the new EU Medical Devices Regulation will impact on “grandfathered” devices that were approved under old regulation and are currently on the market, but do not necessarily comply with current/updated regulatory standards, and explain the potential implications for device manufacturers.
Top